刘庄教授、程亮教授及其合作者在Sci. Adv.上发表论文

作者：

Fei Gong^1#, Liyun Zheng^2#, Jiachen Xu^3,4#, Yumin Wu¹, Qiutong Jin⁵, Jiaqi Lu⁵, Zifan Pei¹, Zhongwei Zhao², Minjiang Chen², Jianfei Tu², Shiji Fang², Weiqian Chen², Kailu Wei¹, Nailin Yang¹, Chuntao Gong⁵, Fazong Wu², Yeyu Zhang², Caifang Ni⁴*, Liang Cheng¹*, Zhuang Liu^1,5*, Jiansong Ji²*

单位：

¹Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.

²Department of Interventional Radiology, Zhejiang University, Lishui Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.

³Department of Vascular Surgery and Interventional Radiology, The Fourth Affiliated Hospital of Soochow University, Du Shu Lake Hospital Affiliated to Soochow University, Suzhou 215125, China.

⁴Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

⁵InnoBM Pharmaceuticals Co. Ltd., Suzhou, Jiangsu 215123, China.

摘要：

Transarterial chemoembolization (TACE) has been extensively used in clinic to treat unresectable hepatocellular carcinoma (HCC). Herein, magnesium microspheres (Mg MSs) were used as embolic devices to enhance lipiodol-mediated TACE. After being dispersed in lipiodol and injected into tumors, Mg MSs would continuously generate hydrogen and magnesium hydroxide, which could neutralize the acidic tumor microenvironment, restore exhausted CD8+ T cells, reverse immunosuppression, and trigger specific T cell–mediated antitumor responses, synergistically resulting in inhibited tumor growth. As demonstrated in a rabbit orthotopic liver cancer model, artery infusion of Mg MS–dispersed lipiodol offered greatly enhanced therapeutic outcome compared to lipiodol-based or polymeric-bead–based TACE. In a pilot clinical study, among 15 eligible patients with HCC, 11 patients achieved complete response and 3 patients achieved partial responses without unexpected treatment-related adverse events during the 1 to 3 months’ follow-up. The objective response rate of Mg-enhanced TACE was ~93.3% in this small-scale trial, much higher than that of current TACE therapies.

影响因子：

12.5

分区情况：

一区

链接：

https://www.science.org/doi/10.1126/sciadv.adv0885